SCHEMBL3336876

SCHEMBL3336876

COCCOc1nc(N)nc2ccc(-c3ccco3)cc12

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.46
HRH1 P35367 2/20 0.44
HRH4 Q9H3N8 2/20 0.44
HRH3 Q9Y5N1 2/20 0.44
MCL1 Q07820 2/20 0.43
KCNH2 Q12809 1/20 0.42
CCNE2 O96020 1/20 0.40
CCNE1 P24864 1/20 0.40
CDK2 P24941 1/20 0.40
TSHR P16473 1/20 0.39
PDPK1 O15530 1/20 0.38
CLK4 Q9HAZ1 3/20 0.38
ALDH1A1 P00352 1/20 0.38
ADORA1 P30542 1/20 0.38
DHFR P00374 1/20 0.37
DYRK1A Q13627 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3336846 0.87 ADORA2A (0.49) ADORA2AHRH1HRH4HRH3KCNH2
SCHEMBL3336794 0.81 KDM4E (0.40) CDK2TSHRALDH1A1
SCHEMBL3337841 0.81 DHFR (0.44) ADORA2ACCNE2CCNE1CDK2TSHR
SCHEMBL3338593 0.80 ADORA2A (0.49) ADORA2AHRH1HRH4HRH3KCNH2
SCHEMBL3333821 0.80 HSP90AB1 (0.47) ADORA2AHRH4TSHRCLK4ALDH1A1
SCHEMBL3334070 0.79 CDK2 (0.59) ADORA2AHRH1HRH4HRH3KCNH2
SCHEMBL3336135 0.79 SQOR (0.46) ADORA2ATSHRDHFR
SCHEMBL3340872 0.79 PIK3CA (0.40) ADORA2ACCNE2CCNE1CDK2TSHR
SCHEMBL3335310 0.78 PIK3CA (0.39) ADORA2ATSHRDHFR
SCHEMBL3337376 0.78 DHFR (0.46) ADORA1DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 ADORA2A 1968/4885HRH1 124/4885HRH4 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.